GSA Capital Partners’s Fulcrum Therapeutics FULC Stock Holding History

GSA Capital Partners’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.05M	Buy	136,664 +36,955	+37%	+$343K	0.07%	473
2025 Q4	$1.13M	Sell	99,709 -16,359	-14%	-$166K	0.1%	297
2025 Q3	$1.07M	Buy	116,068 +83,505	+256%	+$604K	0.09%	360
2025 Q2	$224K	Buy	+32,563	New	+$174K	0.02%	1442
2024 Q4	–	Sell	-17,142	Closed	-$61K	–	1746
2024 Q3	$61K	Sell	17,142 -118,079	-87%	-$876K	﹤0.01%	1513
2024 Q2	$838K	Buy	135,221 +120,059	+792%	+$909K	0.06%	623
2024 Q1	$143K	Buy	+15,162	New	+$135K	0.01%	1454
2022 Q4	–	Sell	-17,879	Closed	-$145K	–	1613
2022 Q3	$145K	Sell	17,879 -4,943	-22%	-$35.4K	0.02%	1303
2022 Q2	$112K	Buy	+22,822	New	+$223K	0.02%	1203

Other funds holding FULC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

FTM

First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

GSA Capital Partners's FULC Position: Q1 2026 in Review

GSA Capital Partners increased its Fulcrum Therapeutics (FULC) stake by 37% in Q1 2026, buying an estimated $343K and bringing the position to 136,664 shares worth $1.05M. The position accounts for 0.07% of the portfolio, ranked #473.

GSA Capital Partners first reported a position in FULC in Q2 2022 and has held it in 9 quarters since. The position peaked at $1.13M in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

GSA Capital Partners held 136,664 shares of Fulcrum Therapeutics worth $1.05M as of Q1 2026.
GSA Capital Partners bought 36,955 Fulcrum Therapeutics shares in Q1 2026, an estimated $343K.
Fulcrum Therapeutics made up 0.07% of GSA Capital Partners's portfolio in Q1 2026, its #473 holding.
GSA Capital Partners first reported a position in Fulcrum Therapeutics in Q2 2022 and has held it in 9 quarters since.
GSA Capital Partners's Fulcrum Therapeutics position peaked at $1.13M in Q4 2025.
169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.